Proceedings of the Tenth International Conference of Drug Regulatory Authorities (ICDRA) - Hong Kong, China, 24 - 27 June 2002
(2002; 166 pages) View the PDF document
Table of Contents
View the documentAbbreviations and acronyms used in this report
Open this folder and view contentsOpening ceremony
Open this folder and view contentsHerbal medicines
Open this folder and view contentsKeynote address
Open this folder and view contentsSafety of blood-derived products
Open this folder and view contentsAntimicrobial resistance - new initiatives
Open this folder and view contentsHarmonization I
Open this folder and view contentsHarmonization II
Open this folder and view contentsProtection of trial subjects in clinical trials
Open this folder and view contentsRegulating biotechnology products
Open this folder and view contentsRegulatory challenges: health sector reform and drug regulatory capacity
Open this folder and view contentsAccess to drugs and vaccines I
Open this folder and view contentsAccess to drugs and vaccines II
Open this folder and view contentsCounterfeit pharmaceutical products
Open this folder and view contentsHomoeopathy
Open this folder and view contentsSafety monitoring
Open this folder and view contentsE-Commerce
Close this folderCurrent topics
View the document“For export only” manufactured drugs and cosmetics that are not legally used in country of manufacture
View the documentWHO Certification Scheme: input for implementation
View the documentValue of joining the Pharmaceutical Inspection Cooperation Scheme (PIC/S) for developing countries: the Malaysian experience
View the documentPharmacopoeial specifications for new drug entities
View the documentImproving the impact of drug regulatory authorities on public health
View the documentStrengthening drug regulatory authorities in small Pacific Island nations
View the documentTransparency of data
View the documentKava
View the documentXenotransplantation and xenotourism: time for concerted regulatory action
View the documentRecommendations
Open this folder and view contentsRegulatory challenges of new technologies
View the documentList of participants
View the documentBack cover
 

Strengthening drug regulatory authorities in small Pacific Island nations

Mr Peter Zinck, Fiji

The South Pacific Islands comprise 14 countries, including Australia, New Zealand, Papua New Guinea, Samoa, Tonga, Solomon Islands and Fiji. The total population is around 26 million, of whom 20 million are in Australia and New Zealand and 4 million in Papua New Guinea. The remaining 2 million are divided among the other 11 countries.

The regulatory authorities of these small import-oriented countries face many challenges, particularly where gross domestic product is low. Drug budgets are limited, purchasing power is small and it is difficult to source products that are of good quality, reliable and from credible suppliers. Furthermore, because human resources are limited, administrative processes and systems, technical capacity and quality control measures are generally inadequate.

Because of these limitations, DRAs in small Pacific Island nations are exploring the opportunities for regional collaboration in the areas of sharing relevant regulatory information, drug registration, pharmacovigilance and GMP inspection in the hope of strengthening their regulatory capacity. Like New Zealand, which has a strategic alliance with Australia, the small Pacific Island nations are looking for potential twinning arrangements with key regulatory authorities in the region.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: August 29, 2014